Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyIC-LNPs
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral, Subcutaneous, Intramuscular
01
Overview
PolyIC-LNPs are lipid nanoparticles encapsulating polyinosinic-polycytidylic acid (poly(I:C)), a synthetic analogue of double-stranded RNA that acts as an immune adjuvant by activating Toll-like receptor 3 (TLR3). The lipid nanoparticle (LNP) formulation is designed to enhance intracellular delivery of poly(I:C) to target cells, protect the payload from degradation, and improve cellular uptake and endosomal escape. PolyIC-LNPs are being studied primarily as immunostimulatory agents or vaccine adjuvants for cancer immunotherapy, infectious disease vaccines, and other applications requiring robust activation of the innate immune response[6][5]. The LNP delivery system typically contains an ionizable cationic lipid, helper phospholipid, cholesterol, and PEGylated lipid, and is designed for optimal loading, stability, and biodistribution of the poly(I:C) payload[9][5].
- Other names
- poly(I:C)-LNPspolyinosinic-polycytidylic acid lipid nanoparticlespoly(I:C) encapsulated lipid nanoparticles
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on polyIC-LNPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyIC-LNPs.